A phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee

Pain

Volumn 154, Issue 9, 2013, Pages 1603-1612

  Spierings, Egilius L H ^a   Fidelholtz, James ^b   Wolfram, Gernot ^c   Smith, Michael D ^c   Brown, Mark T ^c   West, Christine R ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Hightop Medical Research Center   (United States)

^c PFIZER INC   (United States)

Author keywords

Efficacy; Nerve growth factor; Opioid analgesics; Osteoarthritis; Safety; Tanezumab

Indexed keywords

OXYCODONE; PLACEBO; TANEZUMAB;

ADULT; AGED; ALLODYNIA; ARTHRALGIA; ARTICLE; BONE NECROSIS; BURNING SENSATION; CONSTIPATION; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CUBITAL TUNNEL SYNDROME; DIABETIC NEUROPATHY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSESTHESIA; FATIGUE; FEMALE; FORMICATION; HIP OSTEOARTHRITIS; HIP PAIN; HUMAN; HYPERALGESIA; HYPERESTHESIA; HYPERTENSION; HYPESTHESIA; KNEE OSTEOARTHRITIS; KNEE PAIN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEURALGIA; NEURITIS; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; POLYNEUROPATHY; PRIORITY JOURNAL; PRURITUS; RADICULOPATHY; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SENSORY NEUROPATHY; SOMNOLENCE; VOMITING; WESTERN ONTARIO AND MCMASTER UNIVERSITIES OSTEOARTHRITIS INDEX;

EFFICACY; NERVE GROWTH FACTOR; OPIOID ANALGESICS; OSTEOARTHRITIS; SAFETY; TANEZUMAB;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NARCOTICS; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; OXYCODONE; PAIN; PAIN MEASUREMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84881660403     PISSN: 03043959     EISSN: 18726623     Source Type: Journal    
DOI: 10.1016/j.pain.2013.04.035     Document Type: Article

References (39)

1. Y.N. Abdiche, D.S. Malashock, and J. Pons Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors Protein Sci 17 2008 1326 1335
2. M. Afilalo, M.S. Etropolski, B. Kuperwasser, K. Kelly, A. Okamoto, I. Van Hove, A. Steup, B. Lange, C. Rauschkolb, and J. Haeussler Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study Clin Drug Invest 30 2010 489 505
3. R. Altman, E. Asch, D. Bloch, G. Bole, D. Borenstein, K. Brandt, W. Christy, T.D. Cooke, R. Greenwald, M. Hochberg, D. Howell, D. Kaplan, W. Koopman, S. Longley III, H. Mankin, D.J. McShane, T. Medsger Jr, R. Meenan, W. Mikkelsen, W. Moskowitz, W. Murphy, B. Rothschild, M. Segal, L. Sokolff, and F. Wolfe Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association Arthritis Rheum 29 1986 1039 1049
4. N. Bellamy, W.W. Buchanan, C.H. Goldsmith, J. Campbell, and L.W. Stitt Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee J Rheumatol 15 1988 1833 1840
5. Bello A, Ekman E, Radin D, Davignon I, Smith M, Brown M, West C, Verburg K. Long-term tanezumab treatment for osteoarthritis: efficacy and safety results. Presented at: American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) Annual Scientific Meeting, November 9-14. Washington, DC; 2012. Available from: https://ww2.rheumatology.org/apps/ myannualmeeting.
6. H. Breivik, P.C. Borchgrevink, S.M. Allen, L.A. Rosseland, L. Romundstad, E.K. Hals, G. Kvarstein, and A. Stubhaug Assessment of pain Br J Anaesth 101 2008 17 24
7. Brown M, Murphy F, Radin D, Davignon I, Smith M, West C. Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase 3 trial. Arthritis Rheum. 2013. http://dx.doi.org/10. 1002/art.37950. [Epub ahead of print].
8. M. Brown, F. Murphy, D. Radin, I. Davignon, M. Smith, and C. West Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase 3 trial J Pain 13 2012 790 798
9. D. Cubukcu, A. Sarsan, and H. Alkan Relationships between pain, function and radiographic findings in osteoarthritis of the knee: a cross-sectional study Arthritis 2012 2012 984060
10. Division of Anesthesia Analgesia and Addiction Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration. Background materials addendum, March 2, 2012. Available form: http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ ArthritisDrugsAdvisoryCommittee/UCM295203.pdf.
11. R.H. Dworkin, D.C. Turk, K.W. Wyrwich, D. Beaton, C.S. Cleeland, J.T. Farrar, J.A. Haythornthwaite, M.P. Jensen, R.D. Kerns, D.N. Ader, N. Brandenburg, L.B. Burke, D. Cella, J. Chandler, P. Cowan, R. Dimitrova, R. Dionne, S. Hertz, A.R. Jadad, N.P. Katz, H. Kehlet, L.D. Kramer, D.C. Manning, C. McCormick, M.P. McDermott, H.J. McQuay, S. Patel, L. Porter, S. Quessy, B.A. Rappaport, C. Rauschkolb, D.A. Revicki, M. Rothman, K.E. Schmader, B.R. Stacey, J.W. Stauffer, T. von Stein, R.E. White, J. Witter, and S. Zavisic Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations J Pain 9 2008 105 121
12. E. Ekman, J. Gimbel, A. Bello, M. Smith, D. Keller, K. Annis, M. Brown, C. West, and K. Verburg Efficacy and safety of tanezumab in comparison to placebo and naproxen in the treatment of osteoarthritis knee or hip pain: results of two phase 3 studies. NCT00830063 and NCT00863304 J Pain 12 2011 55
13. R.J. Evans, R.M. Moldwin, N. Cossons, A. Darekar, I.W. Mills, and D. Scholfield Proof of concept trial of tanezumab for the treatment of symptoms associated with interstitial cystitis J Urol 185 2011 1716 1721
14. Food and Drug Administration Center for Drug Evaluation and Research. Background materials. Meeting of the Arthritis Advisory Committee (AAC). Available at: http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ArthritisDrugsAdvisoryCommittee/UCM295202.pdf [accessed 10.03.12].
15. J.M. Frade, and Y.A. Barde Nerve growth factor: two receptors, multiple functions Bioessays 20 1998 137 145
16. J.L. Goodwin, J.J. Kraemer, and Z.H. Bajwa The use of opioids in the treatment of osteoarthritis: when, why, and how? Curr Rheumatol Rep 11 2009 5 14
17. F.F. Hefti, A. Rosenthal, P.A. Walicke, S. Wyatt, G. Vergara, D.L. Shelton, and A.M. Davies Novel class of pain drugs based on antagonism of NGF Trends Pharmacol Sci 27 2006 85 91
18. N. Katz, D.G. Borenstein, C. Birbara, C. Bramson, M.A. Nemeth, M.D. Smith, and M.T. Brown Efficacy and safety of tanezumab in the treatment of chronic low back pain PAIN® 152 2011 2248 2258
19. J.H. Kellgren, and J.S. Lawrence Radiological assessment of osteo-arthrosis Ann Rheum Dis 16 1957 494 502
20. N.J. Koewler, K.T. Freeman, R.J. Buus, M.B. Herrera, J.M. Jimenez-Andrade, J.R. Ghilardi, C.M. Peters, L.J. Sullivan, M.A. Kuskowski, J.L. Lewis, and P.W. Mantyh Effects of a monoclonal antibody raised against nerve growth factor on skeletal pain and bone healing after fracture of the C57BL/6J mouse femur J Bone Miner Res 22 2007 1732 1742
21. N.E. Lane, T.J. Schnitzer, C.A. Birbara, M. Mokhtarani, D.L. Shelton, M.D. Smith, and M.T. Brown Tanezumab for treatment of knee osteoarthritis pain N Engl J Med 363 2010 1521 1531
22. P.W. Mantyh, M. Koltzenburg, L.M. Mendell, L. Tive, and D.L. Shelton Antagonism of nerve growth factor-TrkA signaling and the relief of pain Anesthesiology 115 2011 189 204
23. A.K. Matsumoto, N. Babul, and H. Ahdieh Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled phase III trial Pain Med 6 2005 357 366
24. H. Nagashima, M. Suzuki, S. Araki, T. Yamabe, and C. Muto Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose-escalation, placebo-controlled study Osteoarthritis Cartilage 19 2011 1405 1412
25. Pfizer Inc. Tanezumab Arthritis Advisory Committee Briefing Document. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/ArthritisDrugsAdvisoryCommittee/UCM295205.pdf [accessed 10.03.12].
26. T. Pham, D. van der Heijde, R.D. Altman, J.J. Anderson, N. Bellamy, M. Hochberg, L. Simon, V. Strand, T. Woodworth, and M. Dougados OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited Osteoarthritis Cartilage 12 2004 389 399
27. S.H. Roth, R.M. Fleischmann, F.X. Burch, F. Dietz, B. Bockow, R.J. Rapoport, J. Rutstein, and P.G. Lacouture Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation Arch Intern Med 160 2000 853 860
28. M.C. Rowbotham What is a "clinically meaningful" reduction in pain? PAIN® 94 2001 131 132
29. F. Salaffi, A. Stancati, C.A. Silvestri, A. Ciapetti, and W. Grassi Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale Eur J Pain 8 2004 283 291
30. T.J. Schnitzer, N.E. Lane, C. Birbara, M.D. Smith, S.L. Simpson, and M.T. Brown Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain Osteoarthritis Cartilage 19 2011 639 646
31. M.A. Sevcik, J.R. Ghilardi, C.M. Peters, T.H. Lindsay, K.G. Halvorson, B.M. Jonas, K. Kubota, M.A. Kuskowski, L. Boustany, D.L. Shelton, and P.W. Mantyh Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization PAIN® 115 2005 128 141
32. K. Stengaard-Pedersen, R. Ekesbo, A.L. Karvonen, and M. Lyster Celecoxib 200 mg q.d. is efficacious in the management of osteoarthritis of the knee or hip regardless of the time of dosing Rheumatology (Oxford) 43 2004 592 595
33. F. Tubach, P. Ravaud, G. Baron, B. Falissard, I. Logeart, N. Bellamy, C. Bombardier, D. Felson, M. Hochberg, D. van der Heijde, and M. Dougados Evaluation of clinically relevant states in patient reported outcomes in knee and hip osteoarthritis: the patient acceptable symptom state Ann Rheum Dis 64 2005 34 37
34. D.A. Walsh, D.F. McWilliams, M.J. Turley, M.R. Dixon, R.E. Franses, P.I. Mapp, and D. Wilson Angiogenesis and nerve growth factor at the osteochondral junction in rheumatoid arthritis and osteoarthritis Rheumatology (Oxford) 49 2010 1852 1861
35. J.J. Watson, S.J. Allen, and D. Dawbarn Targeting nerve growth factor in pain: what is the therapeutic potential? BioDrugs 22 2008 349 359
36. Y. Yazici, H.S. Greenberg, M.D. Smith, M.T. Brown, C.R. West, and K.M. Verburg Efficacy of tanezumab compared with non-steroidal anti-inflammatory drugs in patients with knee or hip osteoarthritis (NCT00809354) Arthritis Rheum 63 2011 S326
37. W. Zhang, M. Doherty, N. Arden, B. Bannwarth, J. Bijlsma, K.P. Gunther, H.J. Hauselmann, G. Herrero-Beaumont, K. Jordan, P. Kaklamanis, B. Leeb, M. Lequesne, S. Lohmander, B. Mazieres, E. Martin-Mola, K. Pavelka, A. Pendleton, L. Punzi, B. Swoboda, R. Varatojo, G. Verbruggen, I. Zimmermann-Gorska, and M. Dougados EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) Ann Rheum Dis 64 2005 669 681
38. W. Zhang, R.W. Moskowitz, G. Nuki, S. Abramson, R.D. Altman, N. Arden, S. Bierma-Zeinstra, K.D. Brandt, P. Croft, M. Doherty, M. Dougados, M. Hochberg, D.J. Hunter, K. Kwoh, L.S. Lohmander, and P. Tugwell OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines Osteoarthritis Cartilage 16 2008 137 162
39. W. Zhang, J. Robertson, A.C. Jones, P.A. Dieppe, and M. Doherty The placebo effect and its determinants in osteoarthritis: meta-analysis of randomised controlled trials Ann Rheum Dis 67 2008 1716 1723